Acepromazine Maleate Tablets, USP

Manufacturer
Clipper Distributing Company, LLC
Effective date
2019-09-27
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-02 00:09:27

Label at a glance#

ProductAcepromazine Maleate
Active ingredientACEPROMAZINE MALEATE
Label structure16 sections

Dosage and administration

Dogs: 0.25 - 1.0 mg/lb of body weight. Dosage may be repeated as required.

Storage and handling

Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

NADA 117-532, Approved by FDA

For use in dogs only.

Caution:

SPL UNCLASSIFIED SECTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description:

DESCRIPTION SECTION

Acepromazine maleate, a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs. Its rapid action and lack of hypnotic effect are added advantages.

Chemistry:

DESCRIPTION SECTION

2-acetyl-10-(3-dimethylaminopropyl) phenothiazine hydrogen maleate.

Picture of chemical formula.
Picture of chemical formula.

Mode of Action:

DESCRIPTION SECTION

Acepromazine maleate has a depressant effect on the central nervous system and therefore causes sedation, muscular relaxation and a reduction in spontaneous activity. It acts rapidly, exerting a prompt and pronounced calming effect. It is an effective preanesthetic agent and lowers the dosage requirement of general anesthetics.

Indications:

VETERINARY INDICATIONS SECTION

As an aid in tranquilization and as a preanesthetic agent in dogs. Acepromazine Maleate Tablets can be used as an aid in controlling intractable animals during examination, treatment, grooming, x-ray and minor surgical procedures.

Dosage and Administration:

DOSAGE & ADMINISTRATION SECTION

Dogs: 0.25 - 1.0 mg/lb of body weight. Dosage may be repeated as required.

Animal Safety:

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Acute and chronic toxicity studies have shown a very low order of toxicity for acepromazine maleate.

A safety study using elevated dosages of acepromazine maleate demonstrated no adverse reactions even when administered at three times the upper limit of the recommended daily dosage (3.0 mg/lb body weight). The clinical observation for this high dosage was mild depression which disappeared in most dogs 24 hours after termination of dosing.

The only occurrence of adverse reaction during numerous clinical trials was a very mild respiratory distress (reverse sneeze) which was transient in nature and had no effect on the desired action of the drug.

Contraindications:

CONTRAINDICATIONS SECTION

Phenothiazines may potentiate the toxicity of organophosphates. Therefore, do not use acepromazine maleate to control tremors associated with organic phosphate poisoning.

Do not use in conjunction with organophosphorus vermifuges or ectoparasiticides, including flea collars.

Do not use with procaine hydrochloride.

Warning:

WARNINGS SECTION

Do not use in animals intended for human consumption.

Precautions:

PRECAUTIONS SECTION

Tranquilizers are potent central nervous system depressants, and they can cause marked sedation with suppression of the sympathetic nervous system. Tranquilizers can produce prolonged depression or motor restlessness when given in excessive amounts or when given to sensitive animals. Tranquilizers are additive in action to the actions of other depressants and will potentiate general anesthesia. Tranquilizers should be administered in smaller doses and with greater care during general anesthesia and also to animals exhibiting symptoms of stress, debilitation, cardiac disease, sympathetic blockade, hypovolemia or shock. Acepromazine, like other phenothiazine derivatives, is detoxified in the liver; therefore, it should be used with caution on animals with a previous history of liver dysfunction or leukopenia.

Epinephrine is contraindicated for treatment of acute hypotension produced by phenothiazine-derivative tranquilizers since further depression of blood pressure can occur.

Phenothiazines should be used with caution when followed by epidural anesthetic procedures because they may potentiate the arterial hypotensive effects of local anesthetics.

Adverse Reactions:

ADVERSE REACTIONS SECTION

A few rare but serious occurrences of idiosyncratic reactions to acepromazine may occur in dogs following oral or parenteral administration. These potentially serious adverse reactions include behavioral disorders in dogs such as aggression, biting/chewing, and nervousness.

To report suspected adverse reactions, to obtain a Material Safety Data Sheet or for technical assistance, call 1-866-638-2226.

Storage:

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

How Supplied:

HOW SUPPLIED SECTION

Acepromazine Maleate Tablets are available in 10 and 25 mg concentrations, and are quarter-scored for convenience of administration. Both concentrations are available in bottles containing 100 and 500 tablets.

NDC 57319-445-13 – 10 mg – 100 tablets

NDC 57319-445-15 – 10 mg – 500 tablets

NDC 57319-446-13 – 25 mg – 100 tablets

NDC 57319-446-15 – 25 mg – 500 tablets

SPL UNCLASSIFIED SECTION

670113-04

80733607

80728662, R.0

Revised 06/2012

Principal Display Panel - Bottle Label, 10 mg, 500 tablets

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 57319-445-15

Acepromazine Maleate Tablets, USP

10 mg per Tablet

FOR USE IN DOGS ONLY.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Net Contents: 500 Tablets

Picture of 10 mg, 500 ct label
Picture of 10 mg, 500 ct label

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ACEPROMAZINE MALEATEACTIVE INGREDIENT37862HP2OM1
ACEPROMAZINEACTIVE MOIETY54EJ303F0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
57319-44557319-445-13, 57319-445-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.